Who owns the patent for Tolsura (topline) capsules?
I can’t determine which specific patents cover Tolsura capsules from the information provided here. “Tolsura” is a brand name for an oral formulation (a capsule marketed in the US), and patent coverage can include multiple layers (active ingredient, formulation, specific release mechanism, manufacturing process, and method-of-use). To identify the exact patent(s), I’d need at least one of the following: the US (or other country) company name, the drug’s generic name/active ingredient as listed for the product, or the specific patent numbers you’ve seen.
How do I find the exact patent(s) tied to Tolsura capsules?
You typically get the most direct answer by checking:
- The FDA’s Orange Book listing for the product (it lists approved drug patents and exclusivity).
- The patent assignment databases (to see current owners and assignees).
- The relevant country’s patent office records (for filing numbers and claims).
If you tell me the country (US, EU, UK, etc.) and the active ingredient/generic name for Tolsura capsules, I can narrow down what you should look for and what information the Orange Book or patent databases will contain (for example, listed “drug substance,” “drug product,” and “method of use” patents).
When do patents or exclusivity for Tolsura capsules expire?
Patent and exclusivity timing depends on which protection you mean:
- Patent term (including any extensions)
- Regulatory exclusivity (for example, new drug exclusivity, pediatric exclusivity)
- Any exclusivity tied to formulation/indication
Without the specific patent numbers or the Orange Book entry, I can’t give a reliable expiry date.
What kinds of patents usually cover capsules like Tolsura?
For capsule formulations, patent families often include:
- Formulation patents (specific excipient systems, coatings, or granule designs)
- Release-rate or release-mechanism patents (how the capsule delivers the drug over time)
- Manufacturing/process patents (how the capsule is made)
- Method-of-use patents (specific dosing regimens or indications)
Even when the active ingredient is off-patent, formulation/process patents can still block generic or biosimilar-type competition for a period.
Are there generic or competing versions, and what patents do they challenge?
Whether generics exist and which patents they challenge depends on the jurisdiction and whether an ANDA (US) or other application exists. Hatch-Waxman and related frameworks often lead to litigation or settlement tied to specific Orange Book patents. I can map this out if you share the jurisdiction and the active ingredient/generic name.
Quick next step
Send one of these, and I’ll pinpoint the Tolsura capsule patent(s) and summarize what they cover:
1) The generic name/active ingredient for Tolsura capsules, and the country (e.g., US), or
2) The patent numbers you’re looking at, or
3) A link to the FDA Orange Book listing (or the patent listing page you found).